3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
29
Carboplatin
15
Cisplatin
13
Nivolumab
12
atezolizumab
10
Radiotherapy
10
Paclitaxel
10
Ipilimumab
10
venetoclax
9
Pemetrexed
9
Docetaxel
9
durvalumab
8
Gemcitabine
8
fludarabine
7
Specimen Handling
7
Cyclophosphamide
7
Bevacizumab
7
tislelizumab
6
fludarabine phosphate
6
Trastuzumab
6
Practice Guidelines as Topic
6
Cetuximab
6
Biopsy
6
enzalutamide
5
Surveys and Questionnaires
5
Standard of Care
5
Radiosurgery
5
Magnetic Resonance Spectroscopy
5
Dexamethasone
5
Cytarabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Dalteparin
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled